2.20
+0.06(+2.80%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
138
First IPO Date
February 09, 2021
| Name | Title | Pay | Year Born |
| Dr. Peter P. Luo Ph.D. | Co- Founder, Chairman, Chief Executive Officer and President of R&D | 0 | 1966 |
| Dr. Jiping Zha M.D., Ph.D. | Executive Vice President of Clinical Development | 0 | N/A |
| Ms. Yan Li M.B.A. | Senior Vice President of Bioinformatics & Information Technology | 0 | 1975 |
| Dr. Guizhong Liu Ph.D. | Senior Vice President of Early Drug Discovery | 0 | 1971 |
| Ms. Ling Zhou | Executive Director & Head of Human Resources | 0 | N/A |
| Mr. Alexander Goergen | Vice President & Head of Business Development | 0 | 1987 |
| Dr. Qinghai Zhao Ph.D. | Chief Manufacturing Officer | 0 | 1961 |
| Ms. Xiaohong She | Senior Vice President & Head of Clinical Operations | 0 | 1967 |
| Dr. Songmao Zheng Ph.D. | Senior Vice President of Clinical Pharmacology & Quantitative Sciences | 0 | N/A |
| Mr. Man Kin Tam M.B.A. | Chief Financial Officer & Director | 0 | 1977 |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.